Pieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trial

Palvella Therapeutics announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. “We are pleased to have dosed the first patient in our Phase 3 SELVA trial, an important milestone towards our objective of advancing QTORIN rapamycin to potential regulatory approvals and U.S. commercialization,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “QTORIN rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for the estimated more than 30,000 diagnosed patients suffering from microcystic LMs in the U.S.”